Loading…
Decision Guide
Billers repeat the rule of thumb — “one denial costs ten treatments” — but the real ratio depends on your acquisition spread, and it’s usually worse. Here’s the arithmetic behind it, computed on a real drug at the current payment limit.
| Maintenance dose (300 mg = 300 units of J3380) | allowable $6,487 |
| Collected on a clean claim (net of 2% sequester) | $6,383 |
| Implied ASP (allowable ÷ 1.06) ≈ acquisition benchmark | $6,119 |
| Clean-claim margin, acquisition at ASP | $263 |
| Unrecovered denial: acquisition written off | −$6,119 |
| Clean claims erased by one written-off denial | ≈ 23 |
| Same math with acquisition 10% below ASP | margin $875 → ≈ 6 claims |
The popular “ten treatments” figure assumes a healthy acquisition discount. At list-adjacent acquisition, the true number is closer to twenty-five.
Asymmetry. On a clean claim you keep only the spread between reimbursement (~104.3% of ASP after sequestration, with coinsurance collected) and your acquisition — a few percent of the drug's cost. On an unrecovered denial you've already bought the drug and administered it, so the loss is the entire acquisition cost. When the margin is ~4% and the loss is ~100%, one write-off erases roughly twenty-five claims' worth of margin; even with acquisition 10% below ASP, it's still six or seven.
Missing or mismatched JW/JZ modifiers (required on single-dose-container claims since 2023), billing a recoded or deleted HCPCS (codes leave the file every quarter), unit errors (mg-to-billing-unit arithmetic), prior-authorization lapses, and payer sourcing mandates — a white-bag policy you didn't know about turns the whole drug line into a denial.
Directionally yes, often worse: commercial allowables are usually higher, so the acquisition at risk per denial is the same while the process to recover is slower and more variable. The exact ratio depends on each contract's spread — which is practice-specific.
Work every drug denial like it's twenty claims, because it is. At these ratios, denial-recovery effort on buy-and-bill drugs has the highest dollar-per-hour payoff in the revenue cycle — and prevention (modifier discipline, quarterly code checks, mandate tracking) is cheaper still.
Two of the biggest preventable triggers have their own pages: JW/JZ modifier discipline and quarterly code changes. Payer sourcing mandates: the state tracker.
Drug economics as of Q3 2026 (Medicare ASP basis)
The practice X-Ray reads your 835s — including the denials — and prices what they cost you, drug by drug, next to the channel and mandate leaks.